Role of Connexin32 and β-Catenin in Tumor Promotion in Mouse Liver

Toxicologic Pathology

Volumn 31, Issue 1, 2003, Pages 99-102

  Schwarz, Michael ^a   Wanke, Ines ^a   Wulbrand, Ulrich ^a   Moennikes, Oliver ^a   Buchmann, Albrecht ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

beta catenin; connexin32; Ha ras; Mouse hepatocarcinogenesis; phenobarbital; tumor promotion

Indexed keywords

BETA CATENIN; CELL PROTEIN; CONNEXIN 32; DIETHYLNITROSAMINE; PHENOBARBITAL;

CANCER GROWTH; CELL COMMUNICATION; CELL DEATH; CELL DIVISION; CELL TRANSFORMATION; CONFERENCE PAPER; DISEASE ASSOCIATION; GAP JUNCTION; GENE MUTATION; GENE TARGETING; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; ONCOGENE H RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

ANIMALS; BETA CATENIN; CARCINOGENS; CELL DIVISION; COCARCINOGENESIS; CONNEXINS; CYTOSKELETAL PROTEINS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MUTATION; TRANS-ACTIVATORS;

ANIMALIA;

EID: 0037258057     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230390173932     Document Type: Article

References (24)

1. Aydinlik H., Nguyen TD, Moennikes O., Buchmann A., Schwarz M. (2001). Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumors. Oncogene 20: 7812-7816.
2. Bai S., Spray DC, Burk RD (1993). Identification of proximal and distal regulatory elements of the rat connexin32 gene. Biochim Biophys Acta 1216: 197-204.
3. Buchmann A., Bauer-Hofmann R., Mahr J., Drinkwater NR, Luz A., Schwarz M. (1991). Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: Correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 88: 911-915.
4. Budunova IV, Williams GM (1994). Cell culture assays for chemicals with tumor-promoting or tumor-inhibiting activity based on the modulation of intercellular communication. Cell Biol Toxicol 10: 71-116.
5. de-La-Coste A., Romagnolo B., Billuart P., Renard CA, Buendia MA, Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C. (1998). Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95: 8847-8851.
6. Devereux TR, Anna CH, Foley JF, White CM, Sills RC, Barrett JC (1999). Mutation of β-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 18: 4726-4733.
7. Drinkwater NR, Bennet LM (1991). Genetic control of carcinogenesis in experimental animals. Prog Exp Tumor Res 33: 1-20.
8. Gebhardt R., Tanaka T., Williams G. (1989). Glutamine synthetase heterogeneous expression as a marker for the cellular lineage of preneoplastic and neoplastic liver populations. Carcinogenesis 10: 1917-1923.
9. Grasso P., Hardy J. (1975). Strain differences in natural incidence and response to carcinogens. In: Mouse Hepatic Neoplasia, Butler WH, Newberne PM (eds). Elsevier Scientific Publications Co, Amsterdam, Oxford, New York, pp 111-131.
10. Honkakoski P., Negishi M. (2000). Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347: 321-337.
11. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG (1996). A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403-414.
12. Korinek V., Barker N., Morin PJ, van-Wichen D., de-Weger R., Kinzler KW, Vogelstein B., Clevers H. (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
13. Loeppen S., Schneider D., Gaunitz F., Gebhardt R., Kurek R., Buchmann A., Schwarz M. (2002). Overexpression of glutamine synthetase is associated with β-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 62: 5685-5688.
14. Maronpot RR, Fox T., Malarkey DE, Goldsworthy TL (1995) Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101: 125-156.
15. Moennikes O., Buchmann A., Ott T., Willecke K., Schwarz M. (1999). The effect of connexin32 null mutation on hepatocarcinogenesis in different mouse strains. Carcinogenesis 20: 1379-1382.
16. Moennikes O., Buchmann A., Romualdi A., Ott T., Werringloer J., Willecke K., Schwarz M. (2000). Lack of phenobarbital mediated promotion of hepatocarcinogenesis in connexin32 null mice. Cancer Res 60: 5087-5091.
17. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8): S4-S66.
18. Polakis, P. (2000). Wnt signaling and cancer. Genes Dev 14: 1837-1851.
19. Schwarz M., Buchmann A., Stinchcombe S., Luebeck G., Moolgavkar S., Bock KW (1995). Role of receptors in human and rodent hepatocarcinogenesis. Mutat Res 333: 69-79.
20. Swierenga SH, Yamasaki H. (1992). Performance of tests for cell transformation and gap-junctional intercellular communication for detecting nongenotoxic carcinogenic activity. In: Mechanisms of Carcinogenesis in Risk Identification, No. 116, Vainio H, Maggee P, McGregor D, McMichael AJ (eds). IARC Scientific Publications, Lyon, pp 165-193.
21. Temme A., Buchmann A., Gabriel HD, Nelles E., Schwarz M., Willecke K. (1997). High incidence of spontaneous and chemically induced liver tumors in mice deficient for connexin32. Curr Biol 7: 713-716.
22. Trosko JE, Ruch RJ (1998). Cell-cell communication in carcinogenesis. Frontiers Biosci 3: 208-236.
23. van der Heyden MA, Rook MB, Hermans MM, Rijksen G., Boonstra J., Defize LH, Destree OH (1998). Identification of connexin43 as a functional target for Wnt signalling. J Cell Sci 111: 1741-1749.
24. Yamasaki H., Naus CC (1996). Role of connexin genes in growth control. Carcinogenesis 17: 1199-1213.